Emerging evidence
More
Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI
- Evidence type
- News report
- Sources
- 1 sourceJournalism
- Published
- 1 min read
- Truvace record
- TRV-2026-1229cite or check it
Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational...

The gain
Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.
In brief
Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement.
Main points
- Profluent announced a collaboration with BioMarin Pharmaceutical Inc.
- The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline.
- Under the agreement Profluent will apply its foundational AI technology to the effort.
The full story
On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies.
The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline.
Sources
1 on file- MarketScreenermarketscreener.com
ace
What readers say